AIAkira Ishii

Akira Ishii

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Akira Ishii has a total of 242 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact of Aneurysm Size and Flow Diverter Use on Outcomes After Endovascular Therapy of Unruptured Paraclinoid Aneurysms

    by Kazuhiro Fujishima, Kanta Tanaka, Tetsu Satow, Toshiyuki Fujinaka, Katsunori Asai, Tomohiko Ozaki, Jun C. Takahashi, Koji Iihara, Hirotoshi Imamura, Akira Ishii, et al.

    BACKGROUND: Flow diverters (FDs) are increasingly used for unruptured paraclinoid aneurysms, especially large or giant ones. However, their benefit over conventional endovascular therapy remains unclear. This study evaluated outcomes after endovascular therapy of unruptured paraclinoid aneurysms, with aneurysm size as the primary exposure, and further examined the modifying effect of FD use. METHODS: We analyzed data of patients with unruptured paraclinoid aneurysms from the Japanese Registry of Neuroendovascular Therapy 4, a nationwide, multicenter registry enrolling patients who underwent endovascular therapy in 166 Japanese institutions from 2015 to 2019. The primary outcome was worsening in the modified Rankin Scale score ≥1 at 30 days. Secondary outcomes included ischemic and hemorrhagic complications. Outcomes were compared by aneurysm size (P =0.035), though not significant after multivariable adjustment (adjusted odds ratio, 1.26 [95% CI, 0.87–1.84]). Hemorrhagic complication rates were similarly low across groups. There was no significant difference in modified Rankin Scale score worsening by FD use, regardless of aneurysm size. FD use was associated with significantly fewer ischemic complications in aneurysms ≥10 mm (3.2% versus 10.1%, P P =0.88; P for interaction=0.03). CONCLUSIONS: Endovascular embolization of unruptured paraclinoid aneurysms ≥10 mm was associated with a higher morbidity compared with aneurysms <10 mm. FD use may reduce ischemic complications in larger aneurysms; however, this benefit was not clearly reflected in 30-day functional outcomes.

  • Factors Associated with Postoperative Neurologic Improvement after Endovascular Treatment for Spinal Vascular Lesions: Japanese Registry of Neuroendovascular Therapy 2, 3, and 4

    by Wataro Tsuruta, Yuji Matsumaru, Satoshi Miyamoto, Shuhei Egashira, Jun Isozaki, Daiichiro Ishigami, Hisayuki Hosoo, Mikito Hayakawa, Koji Iihara, Akira Ishii, et al.

    Data regarding predictive factors for postoperative neurological improvement after endovascular treatment for spinal vascular lesions are extremely limited. Our aim was to perform a subgroup analysis of spinal vascular lesions from the Japanese Registry of Neuroendovascular Therapy (JR-NET) 2-4 (2007-2019) to review the current status of endovascular treatment for spinal vascular lesions in Japan and to identify factors associated with postoperative neurologic improvement after endovascular treatment for spinal vascular lesions. The treatment statuses of 384 spinal dural arteriovenous fistula (SDAVF), 115 spinal perimedullary arteriovenous fistula (SPAVF), and 56 spinal intramedullary arteriovenous malformation (SIAVM) cases were assessed along with the correlations between each variable and the primary end point of postoperative neurologic improvement. Treatment was radical in 81.9% of SDAVFs, palliative or presurgical in 73.2% of SIAVMs, and radical or palliative/presurgical in 47.0% and 51.3%, respectively, of SPAVF cases. Total occlusion was achieved in 60.2% of SDAVF, 30.4% of SPAVF, and 17.9% of SIAVM cases. Treatment-related complications occurred in 7.3% of SDAVF, 14.8% of SPAVF, and 8.9% of SIAVM cases. Postoperative neurologic improvement was achieved in 52.3% of SDAVF, 28.7% of SPAVF, and 23.2% of SIAVM cases. In multivariate analyses, such improvement in SDAVFs was correlated with total shunt obliteration and the absence of complications. Postoperative neurologic improvement in SPAVFs was associated with the absence of complications and was inversely associated with hemorrhagic onset in multivariate analyses. In SIAVM, a negative correlation with hemorrhagic onset was found in only univariate analysis. For the analysis of treatment outcomes by institutional case volume, total obliteration of SDAVFs and postoperative neurologic improvement of SPAVFs were significantly higher in the high-volume group. In Japan, treatment of spinal vascular lesions was administered with relative safety, and better outcomes were achieved at high-volume centers. In SDAVFs, total shunt obliteration and avoidance of complications are critical factors for achieving neurologic recovery. In SPAVFs, selecting an appropriate treatment strategy based on the vascular architecture is essential to minimize complications for achieving favorable postoperative outcomes. In SIAVMs, disease management should take precedence over radical intervention. Furthermore, the disruption of neurologic recovery by hemorrhagic onset in both SPAVFs and SIAVMs highlights the importance of early diagnosis and timely intervention.


  • Device selection and clinical outcomes of adjunctive techniques for ruptured intracranial aneurysms: Insights from the JR-NET4 nationwide registry

    by Kouhei Nii, Toshio Higashi, Ritsurou Inoue, Hisatomi Arima, Hirotoshi Imamura, Nobuyuki Sakai, Koji Iihara, Akira Ishii, Yuji Matsumaru, Chiaki Sakai, et al.

    Purpose Adjunctive techniques are frequently required in endovascular treatment (EVT) for ruptured intracranial aneurysms (RIAs) with complex morphology. However, comprehensive nationwide data on technique selection and its relationship with outcomes remain limited. We aimed to clarify anatomical and clinical factors associated with technique selection and to evaluate short-term outcomes using a large nationwide registry. Methods The Japanese Registry of Neuroendovascular Therapy (JR-NET) 4 included over 4,000 RIAs treated between 2015 and 2019. After exclusions, 3,600 patients treated with balloon-assisted coil embolization (BAC), double-microcatheter coil embolization (DMC), or stent-assisted coil embolization (SAC) were analyzed. Multinomial logistic regression identified factors associated with treatment selection, and multivariable logistic regression evaluated predictors of favorable outcome (modified Rankin Scale; mRS 0–2) and mortality at 30 days. Results Wide-neck and large RIAs were associated with DMC and SAC, while bifurcation RIAs were more often treated with DMC. BAC remained the most frequently used technique. Thirty-day outcomes were primarily determined by World Federation of Neurosurgical Societies (WFNS) grade and aneurysm morphology, rather than treatment type. WFNS grade IV-V was linked to a markedly lower chance of favorable outcome (OR 0.10, 95% CI 0.07–0.14), whereas neither DMC nor SAC showed an independent effect compared with BAC. Conclusions In this nationwide registry, technique selection was chiefly determined by aneurysm morphology and location, while outcomes were influenced by patient severity and aneurysm complexity. These findings, from the largest nationwide registry of EVT for RIAs, provide real-world evidence to guide treatment planning.

  • Open Access

    Bioresorbable magnesium flow diverter promotes early aneurysm occlusion in rabbits

    by So Matsukawa, Akira Ishii, Ryo Akiyama, Natsuhi Sasaki, Hidehisa Nishi, Hideo Chihara, Tomoko Hayashi, Yoshihito Kawamura, Shinichi Yagi, Shin-Ichi Inoue, et al.

    Background: Bioresorbable flow diverters (BRFDs) may overcome the limitations of permanent flow diverters (FDs). We developed a long period stacking ordered-type magnesium (Mg) alloy with superior strength, processability, and corrosion resistance using rapidly solidified powder metallurgy. Thin Mg wires were coated with poly L-lactic acid (PLLA) by electrospinning to extend bioresorption, and braided into 48 wire Mg-BRFDs. Methods: We compared mechanical properties, angiographic outcomes, and biological responses of Mg-BRFDs with cobalt–chromium/platinum–tungsten FDs (CoCr-FDs) in a rabbit elastase induced aneurysm model and abdominal aorta. Assessments included angiography, optical coherence tomography, scanning electron microscopy, and histopathology at 0.5, 1, and 3 months. Results: Mg-BRFDs had a mean strut diameter of 56 µm (including a 10 µm PLLA coating), porosity of 53.9%, and pore density of 23 pores/mm². Complete occlusion rates in CoCr-FDs were 20% (1/5), 0% (0/7), and 57% (4/7) at 0.5, 1, and 3 months, respectively; corresponding rates with Mg-BRFDs were 50% (3/6), 75% (6/8), and 100% (8/8). Among cases with incomplete occlusion, neointimal coverage rate of the aneurysm neck was significantly greater with Mg-BRFDs (median 70.2% vs 26.1%, P=0.006). No occlusion of side branches covered by FDs occurred in either group. Neointimal ionized calcium binding adapter molecule 1 (Iba-1) positive cell counts were higher with Mg-BRFDs but declined over time (P=0.0003). Conclusions: Mg-BRFDs promoted early neointimal formation during bioresorption, leading to faster and more complete aneurysm occlusion than CoCr-FDs. These findings demonstrate the feasibility of Mg-BRFDs as a promising next generation therapeutic strategy.


  • Open Access

    Stent-Assisted Coiling for Wide-Neck Ruptured Cerebral Aneurysms: An Observational Survey of Data from the Japanese Registry of Neuroendovascular Therapy 4

    by Takenori Ogura, Hirotoshi Imamura, Nobuyuki Sakai, Koji Iihara, Akira Ishii, Yuji Matsumaru, Chiaki Sakai, Tetsu Satow, Shinichi Yoshimura


  • Outcomes of carotid artery stenting in patients aged 80 years or older with asymptomatic carotid artery stenosis

    by Fuminori Shimizu, Kazutaka Uchida, Manabu Shirakawa, Fumihiro Sakakibara, Satoru Fujiwara, Koji Iihara, Hirotoshi Imamura, Akira Ishii, Yuji Matsumaru, Chiaki Sakai, et al.

    Background and objectives: The outcomes of carotid artery stenting (CAS) for asymptomatic patients aged ≥80 years remain unclear. This study aimed to investigate the procedural and functional outcomes of CAS in these patients. Methods: This was a post-hoc analysis of a nationwide retrospective registry of patients with asymptomatic carotid artery stenosis who underwent CAS. The primary outcome was a composite of ischemic stroke and all-cause death. The secondary outcomes were ischemic stroke, all-cause death, acute occlusion, and acute myocardial infarction. Functional outcomes were assessed using the modified Rankin Scale (mRS). The outcomes were assessed 30 days post-procedure and compared between patients aged ≥80 years and <80 years. Results: Overall, 4549 patients were evaluated. Pre-procedural mRS and the prevalence of ≥80% stenosis were higher in the ≥80-year-old group. Calcified lesions and high risk for carotid endarterectomy were more common in the ≥80-year-old group. No significant between-group differences were found in primary and secondary outcomes. However, the functional outcomes were significantly worse in the ≥80-year-old group, with a higher proportion of patients with worse mRS score (ie, decreasing at least one point) at follow-up (11.2% vs 5.0%; adjusted OR 2.24 (95% CI 1.66 to 3.02)). Conclusion: CAS for asymptomatic carotid artery stenosis is associated with poorer 30-day functional outcomes in patients aged ≥80 years than in those aged <80 years, but the composite of ischemic stroke and all-cause death is not significantly different between the two age groups.


  • Open Access

    Pipeline shield reduces diffusion-weighted imaging-detected ischemia after intracranial aneurysm treatment compared with pipeline flex: a propensity score-matched retrospective cohort study

    by Ryo Akiyama, Akira Ishii, Hideo Chihara, Chiaki Sakai, Takayuki Kikuchi, Masakazu Okawa, Taichi Ikedo, Shigeki Takada, So Matsukawa, Yoshiki Arakawa

    Background The Pipeline Flex embolization device with Shield technology (PED Shield, Medtronic, Irvine, CA, USA) is a flow diverter designed to reduce thrombogenicity through phosphorylcholine surface modification. Although in vitro and in vivo studies have demonstrated the thrombogenicity reducing effects of this technology, its effectiveness in real-world clinical practice remains unclear. This study aims to compare the number of post-procedure diffusion-weighted imaging (DWI)-positive lesions between PED Flex(Medtronic, Irvine, CA, USA) and PED Shield to assess the impact of surface modification. Methods This retrospective cohort study included patients with unruptured intracranial aneurysms treated with PED Flex or PED Shield between April 2016 and March 2024 at a single institution. Propensity score matching was performed to control for confounders, and the number of post-procedure DWI-positive lesions was evaluated as the primary outcome. Results In total, 148 procedures (132 patients, 138 aneurysms) were included, with 68 (46%) treated with PED Flex and 80 (54%) with PED Shield. Propensity score matching resulted in 47 matched pairs. After matching, the median number of post-procedure DWI-positive lesions was nine (interquartile range (IQR): 3–17) in the PED Flex group and three (IQR: 1–6) in the PED Shield group, with a significantly lower number in the PED Shield group (regression coefficient β = −10.70 [95% confidence interval (CI): −16.23 to −5.16), PConclusion After adjusting for confounders, the PED Shield group had significantly fewer post-procedure DWI-positive lesions than the PED Flex group, suggesting that phosphorylcholine surface modification technology may reduce thrombogenicity in real-world clinical practice.


  • Thirteen-Year Trends and Advancements of Endovascular Therapy for Dural Arteriovenous Fistulas in Japan: Insights from a Nationwide Study of 6470 Procedures

    by Satoshi Murai, Tomohito Hishikawa, Masafumi Hiramatsu, Jun Haruma, Kenji Sugiu, Koji Iihara, Hirotoshi Imamura, Akira Ishii, Yuji Matsumaru, Chiaki Sakai, et al.

    BACKGROUND AND PURPOSE: Endovascular therapy (EVT) for dural arteriovenous fistulas (dAVFs) has evolved with advancements in imaging technology and devices. However, few large-scale, nationwide studies have been reported. This study aimed to investigate the trends and advancements in EVT for dAVFs over the past 13 years. MATERIALS AND METHODS: We identified patients from the Japanese Registry of Neuroendovascular Therapy (JR-NET) database treated for dAVFs between 2007 and 2019. We compared patient demographics, disease characteristics, treatment methods, and outcomes between JR-NET2 (2007–2009), JR-NET3 (2010–2014) and JR-NET4 (2015–2019). Predictive factors of complications were evaluated using multivariate logistic regression analysis. RESULTS: In total, we analyzed 6,470 procedures. Comparing JR-NET2, 3, and 4, the treatment for tentorial and anterior cranial fossa dAVFs has increased, and the use of precipitating liquid materials in transarterial embolization (TAE) increased to 31.7%. Complete obliteration in TAE alone increased to 38.0%, with no significant changes in complication rates, morbidity, or mortality at 30 days. In JR-NET2&3, complications were significantly associated with the cavernous sinus, tentorium, anterior cranial fossa, and emergency treatment. In JR-NET4, aggressive symptoms and precipitating liquid embolic materials were significantly correlated with complications. Supervision by senior trainers significantly reduced complications. CONCLUSIONS: The use of precipitating liquid embolic materials has improved TAE outcomes. While their use has also emerged as a new risk factor for complications, supervision by senior trainers has been shown to mitigate these risks. ABBREVIATIONS: CVR = cortical venous reflux; dAVFs = dural arteriovenous fistulas; EVT = endovascular therapy; JR-NET = Japanese Registry of Neuroendovascular Therapy = JSNET, Japanese Society for Neuroendovascular Therapy; TAE = transarterial embolization; TVE = transvenous embolization.


  • Open Access

    Early neurological deterioration after endovascular treatment for acute stroke with mild symptoms

    by Satoru Fujiwara, Kazutaka Uchida, Tsuyoshi Ohta, Nobuyuki Ohara, Michi Kawamoto, Hiroshi Yamagami, Mikito Hayakawa, Akira Ishii, Koji Iihara, Hirotoshi Imamura, et al.

    Purpose Endovascular treatment (EVT) for acute ischemic stroke (AIS) with mild symptoms (National Institute of Health Stroke Scale [NIHSS] score of ≤ 5) has a specific concern about early neurological deterioration (END) after the procedure, but its significance remains unclear. This study aims to examine the prognostic impact and characteristics of END in this patient population. Methods We conducted a post-hoc analysis of the Japan Registry of NeuroEndovascular Therapy 4, enrolling 13,479 patients who underwent EVT for AIS at 166 participating centers between 2015 and 2019. We included patients with AIS and NIHSS scores ≤ 5 and compared outcomes (modified Rankin Scale [mRS] score at 30 days) between patients with and without END after EVT. Multivariate logistic regression models were used to explore associations between END and outcomes and risk factors for END. Results Of 503 patients analyzed, 66 (13%) developed END. Patients who developed END had a lower proportion of mRS scores of 0–2 at 30 days than the No-END group (17% vs. 80%, P < 0.0001), with an adjusted odds ratio (OR) of 0.04 (95% confidence interval [CI], 0.02–0.11). Mortality within 30 days was higher among patients with END (9.1% vs. 0.7%, P < 0.0001). A multivariable logistic regression model identified that factors associated with END included age ≥ 75 years (adjusted OR 3.67; 95% CI, 1.78–7.55), ASPECTS (adjusted OR 0.82; 95% CI, 0.69–0.97), NIHSS scores before EVT of 0–2 compared with those of 3–5 (adjusted OR 2.11; 95% CI, 1.04–4.25), and unsuccessful recanalization (adjusted OR 8.39; 95% CI, 3.90–18.0). Conclusion END after EVT for AIS with mild symptoms was relatively common and associated with worse outcomes. Risk stratification for END and successful recanalization would be crucial, particularly for EVT candidates with mild symptoms.


  • Open Access

    Magnesium-based bioresorbable flow diverter for intracranial aneurysms: a pilot study of biocompatibility and bioresorption in a rabbit vascular model

    by Ryo Akiyama, Akira Ishii, Natsuhi Sasaki, So Matsukawa, Shinichi Yagi, Hideo Chihara, Hidehisa Nishi, Kiyotaka Iwasaki, Shinichi Sakurai, Yoshihito Kawamura, et al.

    Background: Bioresorbable flow diverters (BRFDs) have the potential to solve several problems associated with conventional permanent flow diverters. We have constructed bare and poly-L-lactic acid (PLLA)-coated magnesium BRFDs (MgBRFDs) using a high-strength corrosion-resistant magnesium alloy. This study aimed to compare bioresorption and biocompatibility between the two types in a rabbit vascular model to determine which is more clinically feasible in humans. Methods: Bare and PLLA-coated MgBRFDs were fabricated by braiding 48 thin magnesium alloy wires. Mechanical testing was conducted. Bare (n=13) and PLLA-coated (n=13) MgBRFDs were implanted into rabbit aortas and harvested 14, 30, and 90 days after implantation. The physical structure of the resolution process was examined using optical coherence tomography (OCT), micro-computed tomography, and scanning electron microscopy (SEM). The biological response of the vascular tissue was examined using SEM and histopathological analysis. Results: The porosity and pore density of the bare MgBRFD were 64% and 16 pores/mm 2 , respectively; corresponding values for the PLLA-coated MgBRFD were 63% and 12 pores/mm 2 , respectively. The OCT attenuation score was significantly higher for the PLLA-coated MgBRFD at all time points (14 days, P=0.01; 30 days, P=0.02; 90 days, P=0.004). OCT, micro-computed tomography, and SEM demonstrated better stent structure preservation with the PLLA-coated MgBRFD. Neointimal thickness did not significantly change over time in either type of MgBRFD (bare, P=0.93; PLLA-coated, P=0.34); however, the number of inflammatory and proliferative cells peaked at 14 days and then decreased. Conclusions: Both bare and PLLA-coated MgBRFDs had excellent biocompatibility. The PLLA-coated MgBRFD has greater clinical feasibility because of its delayed bioresorption.